Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole vs Vonoprazan in GERD
NCT07563491Completed
- Start
- Jan 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of vonoprazan in gastroesophageal reflux disease (GERD) (2 arms). Primary endpoint: Sufficient relief at 4 weeks. Started Jan 2025; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07563491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563491.